Zhong Guo Jing Ji Wang·2025-09-02 06:13Core Viewpoint - Zhixiang Jintai (688443.SH) reported significant revenue growth in the first half of 2025, with operating income reaching 45.39 million yuan compared to 12,660.54 yuan in the same period last year, although the company continues to face net losses [1][3]. Financial Performance - The company achieved operating income of 45.39 million yuan in H1 2025, a substantial increase from 12,660.54 yuan in H1 2024, indicating a growth rate that is not applicable due to the low base [1][3]. - The net profit attributable to shareholders was -289.29 million yuan, an improvement from -361.93 million yuan in the previous year [1][3]. - The net cash flow from operating activities was -116.06 million yuan, an improvement from -264.35 million yuan year-on-year [1][3]. - The net assets attributable to shareholders decreased by 13.87% to 1.83 billion yuan compared to the end of the previous year [3]. - Total assets slightly decreased by 0.91% to 3.12 billion yuan [3]. Historical Performance - Zhixiang Jintai has reported net losses for four consecutive years from 2021 to 2024, with net profits attributable to shareholders of -322 million yuan, -576 million yuan, -801 million yuan, and -797 million yuan respectively [3][4]. - The company’s net profit excluding non-recurring gains and losses also showed a consistent decline over the same period [3][4]. IPO and Fundraising - The company went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, raising a total of 3.47 billion yuan, with a net amount of 3.29 billion yuan after deducting issuance costs [5]. - The initial fundraising target was 3.98 billion yuan, aimed at projects related to antibody industrialization and working capital [5].